529 related articles for article (PubMed ID: 17533364)
41. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
42. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
[TBL] [Abstract][Full Text] [Related]
43. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
Wolf M; Korja M; Karhu R; Edgren H; Kilpinen S; Ojala K; Mousses S; Kallioniemi A; Haapasalo H
BMC Cancer; 2010 May; 10():181. PubMed ID: 20444257
[TBL] [Abstract][Full Text] [Related]
44. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
45. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.
Beheshti B; Braude I; Marrano P; Thorner P; Zielenska M; Squire JA
Neoplasia; 2003; 5(1):53-62. PubMed ID: 12659670
[TBL] [Abstract][Full Text] [Related]
46. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
Godfried MB; Veenstra M; v Sluis P; Boon K; v Asperen R; Hermus MC; v Schaik BD; Voûte TP; Schwab M; Versteeg R; Caron HN
Oncogene; 2002 Mar; 21(13):2097-101. PubMed ID: 11960382
[TBL] [Abstract][Full Text] [Related]
47. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.
Cobrinik D; Ostrovnaya I; Hassimi M; Tickoo SK; Cheung IY; Cheung NK
Genes Chromosomes Cancer; 2013 Dec; 52(12):1150-66. PubMed ID: 24123354
[TBL] [Abstract][Full Text] [Related]
48. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
49. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
50. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
51. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
52. Concomitant DDX1 and MYCN gain in neuroblastoma.
Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
[TBL] [Abstract][Full Text] [Related]
53. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
[TBL] [Abstract][Full Text] [Related]
54. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
[TBL] [Abstract][Full Text] [Related]
55. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
56. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.
Łastowska M; Chung YJ; Cheng Ching N; Haber M; Norris MD; Kees UR; Pearson AD; Jackson MS
Genes Chromosomes Cancer; 2004 Jun; 40(2):158-63. PubMed ID: 15101050
[TBL] [Abstract][Full Text] [Related]
57. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
[TBL] [Abstract][Full Text] [Related]
58. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
60. Origin and functional significance of large-scale chromosomal imbalances in neuroblastoma.
Stallings RL
Cytogenet Genome Res; 2007; 118(2-4):110-5. PubMed ID: 18000361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
